

## Condensed Statement of Profit and Loss and Other comprehensive income

Condensed Statement of Cash Flows

				-				
	Audited	Audited		Audited	Audited		Audited	Audited
	as at	as at		For the year ended	For the year ended		For the year ended	For the year ended
	31 December	31 December		31 December	31 December		31 December	31 December
	2024	2023		2024	2023		2024	2023
	EUR	EUR		EUR	EUR		EUR	EUR
Assets			INCOME			Operating activities		
Non Current			Net gain on investment	130,896	305,873	Profit before tax	4,485,464	5,020,803
Financial assets at fair value through profit and loss	3,816,568	3,685,672	Interest income	4,357,305	4,455,958			
Held-to-maturity investments	52,931,758	51,437,347	Total income	4,488,201	4,761,831	Adjustment for:		
Loan receivable	17,288,863	22,495,358				Reversal of impairment losses of financial assets	(435,828)	(246,014
Notes receivables	72,981,960	71,613,633	EXPENSES			Impairment losses of financial assets	141,475	165,806
Non-current assets	147,019,149	149,232,010	Impairment loss of financial assets	141,475	165,806	Net losses on investments	(130,896)	(305,873
			Legal and professional fees	5,881	3,758	Interest income	(4,357,305)	(4,455,958
Current			Management fees	58,721	59,073	Exchange difference on balances	(35,740)	(309,585
Notes receivable	2,277,967	2,282,541	Custodian fees	34,409	34,922	Total adjustments	(4,818,294)	(5,151,624
Loans receivable	8,357,982	8,374,863	Investment advisory fees	56,029	56,434		-	
Other receivables	1,449	1,721	Listing fees	9,318	9,134	Changes in working capital:		
Interest receivable	5,358,531	5,483,647	Administration fees	2,992	2,766	Change in other receivables	273	(669
Current tax asset	6,191	5,302	License fees	2,787	1,626	Change in payables and accruals	(109)	(71
Cash and cash equivalents	44,717	362,760	Audit fees	3,960	3,721	Subscription in advance	606,061	
Current assets	16,046,837	16,510,834	Other expenses	3,951	2,906	Change in interest payable	-	1,061
Total assets	163,065,986	165,742,844	Total expenses	319,523	340,146	Change in interest receivable	125,116	(394,195
						Total change in working capital	731,341	(393,874)
Equity and Liabilities			Operating profit	4,168,678	4,421,685	Net taxes paid	(90,959)	(205,092)
Equity			Reversal of impairment losses	435,828	246,014	Net cash generated from/(used in) operating activities	307,552	(729,787
Participating shares	130,010,626	136,889,960	Finance income	(29,194)	(9,403)		-	
Retained earnings	31,410,298	27,713,774	Net foreign exchange losses	(89,848)	362,507	Investing activities		
Total equity	161,420,924	164,603,734	Profit before tax	4,485,464	5,020,803	Investment in financial assets at fair value through profit and loss		(3,379,799
			Tax expense	(90,070)	(128,351)	Investment in promissory notes	(900,000)	
Current			Profit for the year	4,395,394	4,892,452	Loan/notes repaid	7,139,577	8,194,583
Borrowings	1,000,000	1,100,000	Other comprehensive income:			Interest received	813,032	522,350
Subscription in advance	606,061		Items that will not be reclassified subsequently to profit or loss:	-	-	Net cash generated from investing activities	7,052,609	5,337,134
Current tax liability		-	Items that will be reclassified subsequently to profit or loss:	-	-			
Payables and accruals	39,001	39,110	Other comprehensive income for the year net of tax	-		Financing activities		
Current liabilities	1,645,062	1,139,110	Total comprehensive income for the year	4,395,394	4,892,452	Proceeds from issue of participating shares	958,320	1,500,000
Total liabilities	1,645,062	1,139,110				Redemption of participating shares	(8,536,524)	(6,986,900
Total equity and liabilities	163,065,986	165,742,844				Proceed from loan	1,000,000	1,100,000
Net assets value per share	1,407	1,369				Repayment of loan	(1,100,000)	
						Net cash flows used in financing activities	(7,678,204)	(4,386,900
							(242.242)	220.447
						Net change in cash and cash equivalents	(318,043)	220,447
						Cash and cash equivalent at the beginning of the year	362,760	142,313
						Cash and cash equivalent at end of year	44,717	362,760
						Cash and cash equivalents made up of:		
						Cash at bank	44,717	362,760

## Condensed Statement of Changes in Equity

	Participating	Retained	
	shares	earnings	Total
	EUR	EUR	EUR
At 01 January 2024	136,889,960	27,713,774	164,603,734
Issue of shares	958,320		958,320
Redemption of shares	(7,837,654)	(698,870)	(8,536,524)
Transaction with the shareholders	(6,879,334)	(698,870)	(7,578,204)
Profit for the year	-	4,395,394	4,395,394
Other comprehensive income for the year	-		-
Total comprehensive income for the year	-	4,395,394	4,395,394
At 31 December 2024	130,010,626	31,410,298	161,420,924

Dentisiantian

Deteined

At 01 January 2023	142,058,726	23,139,456	165,198,182
Issue of shares	1,500,000	-	1,500,000
Redemption of shares	(6,668,766)	(318,134)	(6,986,900)
Transaction with the shareholders	(5,168,766)	(318,134)	(5,486,900)
Profit for the year	-	4,892,452	4,892,452
Other comprehensive income for the year	-	-	-
Total comprehensive income for the year	-	4,892,452	-
At 31 December 2023	136,889,960	27,713,774	164,603,734

By order of the board . Perigeum Capital Ltd SEM authorised representative and sponsor Date: 20 March 2025



2. The audited condensed financial statements for the year ended 31 December 2024 were approved by the board on 20 March 2025. 3. Nexia Baker & Arenson have issued their unmodified audit opinion on the financial statement for the year 31 December 2024.

accounting policies as those of the audited financial statements for the year ended 31 December 2023.

Copies of the audited condensed financial statements for the year ended 31 December 2024 are available free of charges at the registered office of Warwyck Phoenix VCC at Warwyck House, Nalletamby Road, Phoenix. This communiqué is issued pursuant to SEM Listing Rules 11.3 and 12.14. The board of Warwyck Phoenix VCC accepts full responsibility for the accuracy of the information contained in this communiqué. The directors are not aware of any matters or circumstances

arising subsequent to 31 December 2024 that require any additional disclosure or adjustment to the financial statements.

1. The investment objective of Warwyck Phoenix Global Invest Fund 2 ("Sub-fund 7") seeks to achieve long-term capital appreciation by investing in the Textile & Hotel Industries and into related Real Estate Business. In pursuing its objective, Sub-fund 7 seeks to generate attractive long-term returns with low sensitivity to traditional equity and fixed-income indices. Sub-fund 7 has an intermediate and long investment horizon and will focus on growth. Sub-fund 7 is suitable for investors with high risk tolerance.

4. These financial statements have been prepared in accordance with the measurement and recognition requirements of International Financial Reporting Standards, the requirements of IAS 34: Interim Financial Reporting, the SEM Listing Rules and using the same